Eligibility for recombinant tissue plasminogen activator in acute ischemic stroke: a population-based study

Acute ischemic stroke patients are infrequently treated with recombinant tissue plasminogen activator (rtPA). We present unique population-based data regarding the eligibility of ischemic stroke patients for rtPA treatment. All ischemic strokes presenting to an emergency department (ED) within a bir...

Full description

Saved in:
Bibliographic Details
Published in:Stroke (1970) 2004-02, Vol.35 (2), p.e27-e29
Main Authors: Kleindorfer, Dawn, Kissela, Brett, Schneider, Alex, Woo, Daniel, Khoury, Jane, Miller, Rosemary, Alwell, Kathleen, Gebel, James, Szaflarski, Jerzy, Pancioli, Arthur, Jauch, Edward, Moomaw, Charles, Shukla, Rakesh, Broderick, Joseph P
Format: Article
Language:English
Subjects:
Acute Disease
Brain Ischemia - complications
Brain Ischemia - drug therapy
Eligibility Determination
Emergency Service, Hospital - standards
Emergency Service, Hospital - statistics & numerical data
Humans
Ohio
Patient Selection
Recombinant Proteins - therapeutic use
Stroke - complications
Stroke - drug therapy
Time Factors
Tissue Plasminogen Activator - therapeutic use
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Acute ischemic stroke patients are infrequently treated with recombinant tissue plasminogen activator (rtPA). We present unique population-based data regarding the eligibility of ischemic stroke patients for rtPA treatment. All ischemic strokes presenting to an emergency department (ED) within a biracial population of 1.3 million were identified. The patient was considered eligible for rtPA on the basis of exclusion criteria from the National Institute of Neurological Disorders and Stroke rtPA trial. Of 2308 ischemic strokes, 1849 presented to an ED. Only 22% of all ischemic strokes in the population arrived in the ED in
ISSN:0039-2499
1524-4628
DOI:10.1161/01.STR.0000109767.11426.17